Profiles of HBV DNA integration in humans with hepatitis B virus infection: Insights for antiviral treatment
HBV integration profiles in the natural history of chronic HBV infection have not been well-defined. We utilized next-generation sequencing in a well-characterized cohort of patients with HBV at different disease phases, demonstrating a stepwise decrease in integration events as HBV progressed from HBeAg-positive to HBeAg-negative, and then to HBsAg-negative phases. Human and viral genome breakpoints were also identified. These findings enhance our understanding of the natural history of CHB, and provide insights for antiviral treatment.
Authors
- Daniel Wai‐Hung Ho (ORCID: https://orcid.org/0000-0003-3884-296X)
- Rex Wan‐Hin Hui (ORCID: https://orcid.org/0000-0001-7447-7539)
- Lung‐Yi Mak (ORCID: https://orcid.org/0000-0002-2266-3935)
- Man‐Fung Yuen (ORCID: https://orcid.org/0000-0001-7985-7725)
- James Fung (ORCID: https://orcid.org/0000-0002-1286-8902)
- Xueying Lyu (ORCID: https://orcid.org/0000-0002-2885-3940)
- Wai‐Kay Seto (ORCID: https://orcid.org/0000-0002-9012-313X)
- Danny Ka‐Ho Wong
Institutions
- University of Hong Kong - Shenzhen Hospital (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- JHEP Reports
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1016/j.jhepr.2025.101487
- Citations
- 3
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.06
Funders
- Pfizer
- AstraZeneca
- Gilead Sciences
- Alexion Pharmaceuticals
- Sysmex Corporation